NO982913L - Kinolin- og kinazolinforbindelser nyttige i terapi - Google Patents

Kinolin- og kinazolinforbindelser nyttige i terapi

Info

Publication number
NO982913L
NO982913L NO982913A NO982913A NO982913L NO 982913 L NO982913 L NO 982913L NO 982913 A NO982913 A NO 982913A NO 982913 A NO982913 A NO 982913A NO 982913 L NO982913 L NO 982913L
Authority
NO
Norway
Prior art keywords
optionally substituted
group
ring
alkoxy
quinoline
Prior art date
Application number
NO982913A
Other languages
English (en)
Norwegian (no)
Other versions
NO982913D0 (no
Inventor
Alan John Collis
David Nathan Abraham Fox
Julie Newman
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO982913D0 publication Critical patent/NO982913D0/no
Publication of NO982913L publication Critical patent/NO982913L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO982913A 1995-12-23 1998-06-22 Kinolin- og kinazolinforbindelser nyttige i terapi NO982913L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy
PCT/EP1996/005609 WO1997023462A1 (en) 1995-12-23 1996-12-05 Quinoline and quinazoline compounds useful in therapy

Publications (2)

Publication Number Publication Date
NO982913D0 NO982913D0 (no) 1998-06-22
NO982913L true NO982913L (no) 1998-07-30

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982913A NO982913L (no) 1995-12-23 1998-06-22 Kinolin- og kinazolinforbindelser nyttige i terapi

Country Status (34)

Country Link
US (3) US6103738A (de)
EP (1) EP0877734B1 (de)
JP (1) JP3070958B2 (de)
KR (1) KR19990076693A (de)
AP (1) AP715A (de)
AR (1) AR005166A1 (de)
AT (1) ATE194598T1 (de)
AU (1) AU708979B2 (de)
BG (1) BG102559A (de)
BR (1) BR9612263A (de)
CA (1) CA2236814C (de)
CO (1) CO4480106A1 (de)
CZ (1) CZ197698A3 (de)
DE (1) DE69609353T2 (de)
DK (1) DK0877734T3 (de)
ES (1) ES2151192T3 (de)
GB (1) GB9526546D0 (de)
GR (1) GR3034225T3 (de)
HN (1) HN1996000082A (de)
HR (1) HRP960616A2 (de)
HU (1) HUP9903560A3 (de)
IS (1) IS4731A (de)
MA (1) MA26414A1 (de)
NO (1) NO982913L (de)
NZ (1) NZ325248A (de)
OA (1) OA10703A (de)
PL (1) PL327610A1 (de)
PT (1) PT877734E (de)
SK (1) SK81698A3 (de)
TN (1) TNSN96161A1 (de)
TR (1) TR199801195T2 (de)
WO (1) WO1997023462A1 (de)
YU (1) YU68896A (de)
ZA (1) ZA9610784B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
BR0113585A (pt) * 2000-08-31 2003-07-29 Hoffmann La Roche Derivados quinazolina como antagonistas adrenérgicos alfa-1
CA2432578C (en) * 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP2280003B1 (de) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
BR0314759A (pt) 2002-09-26 2005-07-26 Pfizer Derivados de pirazol
PL1615909T3 (pl) 2003-04-23 2009-01-30 Glaxo Group Ltd Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
RS56037B1 (sr) * 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
EP3219705B1 (de) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmazeutische zusammensetzungen der amorphen form von n-[2,4-bis-(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxochinolin-3-carboxamid
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
CN101679308B (zh) * 2007-03-14 2014-05-07 埃克塞里艾克西斯公司 Hedgehog途径抑制剂
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
BRPI0922010A2 (pt) 2008-11-14 2015-12-15 Hoffmann La Roche dervivados de quinazolina como antagonistas receptores de nk3
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8426590B2 (en) * 2009-03-23 2013-04-23 Cipla Limited Process for the preparation of doxazosin and salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SMT201700026T1 (it) * 2009-09-03 2017-03-08 Bristol Myers Squibb Co Chinazoline come inibitori dei canali degli ioni potassio
US8591932B2 (en) 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
EP2683420B1 (de) 2011-03-11 2018-05-23 W. L. Gore & Associates, Inc. Verbesserungen an immobilisierten biologischen einheiten
US20140309184A1 (en) * 2011-09-21 2014-10-16 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
US9938292B2 (en) 2014-03-24 2018-04-10 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as SMO inhibitors
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
SG11202107614PA (en) * 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy

Also Published As

Publication number Publication date
YU68896A (sh) 1999-07-28
ES2151192T3 (es) 2000-12-16
JP3070958B2 (ja) 2000-07-31
DE69609353T2 (de) 2000-12-07
US6642242B2 (en) 2003-11-04
HRP960616A2 (en) 1998-06-30
TR199801195T2 (xx) 1998-10-21
TNSN96161A1 (fr) 2005-03-15
GR3034225T3 (en) 2000-12-29
AP9600900A0 (en) 1997-01-31
US20030220332A1 (en) 2003-11-27
JPH11501668A (ja) 1999-02-09
NZ325248A (en) 1999-09-29
HUP9903560A3 (en) 2000-07-28
PT877734E (pt) 2000-12-29
OA10703A (en) 2002-11-28
US6750214B2 (en) 2004-06-15
US6103738A (en) 2000-08-15
GB9526546D0 (en) 1996-02-28
BG102559A (en) 1999-03-31
DE69609353D1 (de) 2000-08-17
EP0877734B1 (de) 2000-07-12
IS4731A (is) 1998-04-29
BR9612263A (pt) 1999-07-13
SK81698A3 (en) 2000-04-10
HUP9903560A2 (hu) 2000-05-28
EP0877734A1 (de) 1998-11-18
KR19990076693A (ko) 1999-10-15
WO1997023462A1 (en) 1997-07-03
CA2236814C (en) 2001-09-18
CA2236814A1 (en) 1997-07-03
CO4480106A1 (es) 1997-07-09
AU708979B2 (en) 1999-08-19
US20020049322A1 (en) 2002-04-25
AR005166A1 (es) 1999-04-14
HN1996000082A (es) 1997-06-30
AP715A (en) 1998-12-30
CZ197698A3 (cs) 1999-03-17
AU1371997A (en) 1997-07-17
MA26414A1 (fr) 2004-12-20
PL327610A1 (en) 1998-12-21
ZA9610784B (en) 1998-06-22
ATE194598T1 (de) 2000-07-15
NO982913D0 (no) 1998-06-22
DK0877734T3 (da) 2000-11-20

Similar Documents

Publication Publication Date Title
NO982913L (no) Kinolin- og kinazolinforbindelser nyttige i terapi
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
NO972909L (no) Substituerte azetidin-2-oner for behandling av atherosklerose
NO980954L (no) Nye-4-(oksyalkoksyfenyl)-3-oksy-piperidiner for behandling av hjerte- og nyreinsuffisiens
BG102792A (bg) Производни на заместени 4-хидроксифенилалканоилови киселини с агонистична активност към рраr-гама
DE60226875D1 (de) Orthosubstituierte arylamide zur bekämpfung von wirbellosen schädlingen
HUP9903836A2 (hu) Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
EA199800109A1 (ru) Производные азетидинона для лечения атеросклероза
ATE182889T1 (de) Bicyclische amidinderivate als no-synthetase inhibitoren
NO990335L (no) Arylsykloalkankarboksylestere, anvendelse derav, farmas°ytiske sammensetninger og fremstilling
ATE319680T1 (de) Substituierte 2-benzylamino-2-phenyl- acetamidverbindungen
ATE233242T1 (de) Chinoline und chinazoline verbindungen und ihre therapeutische anwendung
HUP9801072A2 (hu) Szubsztituált 6-és 7-amino-tetrahidro-izokinolin-karbonsav-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
NO995289L (no) Benzimidazol-derivater
HUP9700983A2 (hu) 1,4-Diaril-2-fluor-2-butén-származékok, intermedierjeik, előállításuk és alkalmazásuk, valamint hatóanyagként ezeket a vegyületeket tartalmazó inszekticid és akaricid készítmények
EA200101050A1 (ru) Замещенные бензолактамные соединения
TR199801683A2 (xx) Yeni �re t�revleri.
BR9812928A (pt) Novos derivados de 3-oxo-(2h) -1,2,4-triazina, processo de preparação de compostos quìmicos, e, composição farmacêutica
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
NO983919L (no) 7-fenyl-1,4-diazepanderivater, fremgangsmÕter for fremstilling av disse samt legemidler inneholdende slike forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application